Search clinical trials for: CAR-T

Total 17064 results

Roger Williams Medical Center
Sirtex Medical

Completed

CAR-T Hepatic Artery Infusions and Sir-Spheres for Liver Metastases (HITM-SIR)

Liver Metastases

United States
Baylor College of Medicine
The Methodist Hospital Research Institute

Recruiting

CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30) (RELY-30)

Hodgkin's Lymphoma | Non-Hodgkin Lymphoma

United States
Kecellitics Biotech Company Ltd
Hebei Yanda Ludaopei Hospital

Not yet recruiting

Safety and Efficacy of Sequential CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Lymphoma

Lymphoma, B-Cell

China
Baylor College of Medicine
The Methodist Hospital Research Institute

Withdrawn

Allogeneic CD30 Chimeric Antigen Receptor Epstein-Barr Virus-Specific T Lymphocytes in Relapsed or Refractory CD30-Positive Lymphomas

Classical Hodgkin Lymphoma | Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type

United States
Seattle Children's Hospital

Active, not recruiting

A Phase 1 Study of CD22-CAR TCell Immunotherapy for CD22+ Leukemia and Lymphoma (PLAT-04)

Leukemia

United States
Evangelismos Hospital

Not yet recruiting

The Effect of High Flow Oxygen Therapy Via Tracheostomy on Diaphragm Function

Weaning Failure
Vertebral Technologies, Inc.

Unknown

A Prospective Study of the InterFuse T(tm),

Low Back Pain

United States
The Children's Hospital of Zhejiang University...
Leman Biotech Co., Ltd

Recruiting

Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Relapsed and/or Refractory CD19-positive B Cell Hematological Malignancies Clinical Research

Acute Lymphoblastic Leukemia | Non-hodgkin Lymphoma

China
Anhui Provincial Hospital
Leman Biotech Co., Ltd

Recruiting

Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Relapsed and/or Refractory CD19-positive B Cell Hematological Malignancies Clinical Research

Acute Lymphoblastic Leukemia | Non-hodgkin Lymphoma

China
British Columbia Cancer Agency

Not yet recruiting

CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies

B-cell Lymphoma | Non-Hodgkin's Lymphoma | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | B-Cell Leukemia | B-cell Acute Lymphoblastic Leukemia | Primary Mediastinal Large B-cell Lymphoma (PMBCL) | High-grade B-cell Lymphoma

Canada
Baylor College of Medicine
The Methodist Hospital Research Institute; Center for Cell and Gene Therapy...

Not yet recruiting

Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas

Hodgkin Lymphoma | Non-Hodgkin Lymphoma | Peripheral T-cell Lymphoma | Anaplastic Large Cell Lymphoma, ALK-Positive | Anaplastic Large Cell Lymphoma, ALK-negative | CD30-Positive Diffuse Large B-Cell Lymphoma | Anaplastic Large Cell Lymphoma, T Cell and Null Cell Type

United States
The Affiliated Hospital of Xuzhou Medical University

Recruiting

Clinical Study of Anti-CD56-CAR-T in the Treatment of Relapsed/Refractory NK/T Cell Lymphoma /NK Cell Leukemia

NK-Cell Leukemia | Extranodal NK T Cell Lymphoma

China
Zhejiang University
UTC Therapeutics Inc.

Recruiting

UCLM802 (Anti-Mesothelin CAR-T) Cell Injection in Patients With Mesothelin-positive Advanced Malignant Solid Tumors

Mesothelin-positive Advanced Malignant Solid Tumors

China
Wuhan Union Hospital, China
Wuhan Si'an Medical Technology Co., Ltd

Recruiting

T Cells Expressing a Bispecific CAR Targeting CS1 and BCMA in Relapsed/Refractory Multiple Myeloma

CS1+ or BCMA+ Multiple Myeloma

China
RenJi Hospital
CARsgen Therapeutics Co., Ltd.

Completed

CAR-GPC3 T Cells in Patients With Refractory Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Southwest Hospital, China

Unknown

a Clinical Research of Sequential CAR-T Bridging HSCT in the Treatment of Relapse/Refractory B-cell Malignancies

Lymphoma, Large B-Cell, Diffuse | Leukemia, Lymphocytic, Chronic, B-Cell | Lymphoma，Malignant

China
The First Affiliated Hospital of Soochow University
West China Hospital; Affiliated Hospital of Jiangnan University; The Affiliated... and other collaborators

Recruiting

Clinical Study of XPO-1 Inhibitors Plus CAR-T Cells in Relapsed Refractory B-cell Non-Hodgkin's Lymphoma

Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

China
He Huang
Leman Biotech Co., Ltd

Recruiting

Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r DLBCL Clinical Research

Diffuse Large B-cell Lymphoma

China
Anhui Provincial Hospital
Leman Biotech Co., Ltd

Recruiting

Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10- 19) in the Treatment of r/r B-ALL Clinical Research

B-cell Acute Lymphoblastic Leukemia

China
Beijing Immunochina Medical Science & Technology...

Recruiting

Safety and Efficacy Evaluation of IM83 CAR-T Cells for Patients With Advanced Liver Tumors

Liver Cancer

China
Ottawa Hospital Research Institute

Recruiting

CLIC-1901 for the Treatment of Patients With Relapsed/Refractory CD19 Positive Hematologic Malignancies (CLIC-01)

Non-Hodgkin's Lymphoma | Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia

Canada
Shenzhen Institute for Innovation and Translational...
Dongguan People's Hospital

Completed

Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies

Lymphoma | Chronic Lymphocytic Leukemia | Acute Lymphocytic Leukemia

China
Second Affiliated Hospital of Guangzhou Medical...
Guangzhou First People's Hospital; First People's Hospital of Foshan; Dongguan... and other collaborators

Unknown

A Study of Anti-CD19 CAR-T Cell Immunotherapy for Refractory /Relapsed B Cell Malignancies

Lymphoma | Chronic Lymphocytic Leukemia | Acute Lymphocytic Leukemia

China
Baylor College of Medicine
The Methodist Hospital Research Institute; Center for Cell and Gene Therapy...

Recruiting

Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN) (SAGAN)

Chronic Lymphocytic Leukemia | Non-Hodgkin Lymphoma | Acute Lymphocytic Leukemia

United States
Essen Biotech

Not yet recruiting

Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE) (BAH242)

Autoimmune Diseases | Systemic Lupus Erythematosus | Systemic Sclerosis | Lupus Nephritis | Microscopic Polyangiitis | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | Sjogren's Syndrome | Idiopathic Inflammatory Myopathies | Granulomatous Polyangiitis

China
Anhui Provincial Hospital
Leman Biotech Co., Ltd

Recruiting

Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r DLBCL Clinical Research

Diffuse Large B-cell Lymphoma

China
Sun Yat-sen University
Guangzhou Yiyang Biological Technology Co., Ltd.

Terminated

CAR-T Cell Immunotherapy for Advanced Lung Cancer

Advanced Lung Cancer

China
The Affiliated Hospital of Xuzhou Medical University

Recruiting

Clinical Study of the Safety and Efficacy of the R/R B-NHL Regimen With BTK Inhibitor+Anti-CD19 CAR-T Cells

B-cell Non Hodgkin Lymphoma

China
Affiliated Hospital of Jiangnan University
West China Hospital; Hunan Cancer Hospital; Shenzhen Second People's Hospital; Zhejiang... and other collaborators

Recruiting

IFN-γ Combined With T Cells in the Treatment of Refractory Malignant Pleural Effusion and Ascites

Pleural Effusion, Malignant

China
University of Alberta
Alberta Cancer Foundation; Canadian Cancer Trials Group

Recruiting

Anti-CD19, Dual Co-stimulatory (4-1BB, CD3ζ) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL) (ACIT001/EXC002)

Relapsed Non Hodgkin Lymphoma | Relapsed Pediatric ALL | Relapsed Adult ALL

Canada
Second Affiliated Hospital, School of Medicine,...
Carbiogene Therapeutics Co. Ltd.

Recruiting

Novel BCMA-targeted CAR-T Cell Therapy for Multiple Myeloma

Relapsed or Refractory Multiple Myeloma

China
Shanghai GeneChem Co., Ltd.
RenJi Hospital

Unknown

A Study of CD19 Redirected Autologous T Cells for CD19 Positive Systemic Lupus Erythematosus (SLE)

Systemic Lupus Erythematosus (SLE)

China
The Third Affiliated Hospital of Guangzhou Medical...
Hangzhou Cheetah Cell Therapeutics Co., Ltd

Recruiting

NKG2D CAR-T Cells to Treat Patients With Previously Treated Liver Metastatic Colorectal Cancer

Refractory Metastatic Colorectal Cancer

China
Xinqiao Hospital of Chongqing
Xuzhou Medical University

Unknown

Anti-CD22 CAR-T Therapy for CD19-refractory or Resistant Lymphoma Patients (MendCART)

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Follicular Lymphoma | Stage III/IV Adult Diffuse Large Cell Lymphoma | Stage III/IV Follicular Lymphoma | Stage III/IV Mantle Cell Lymphoma

China
Institute of Hematology & Blood Diseases Hospital...

Recruiting

A Study of VRd-based Regimen Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With New-diagnosed Multiple Myeloma

Multiple Myeloma

China
South Dakota State University
Sanford Health

Unknown

Effect of a Synbiotic Supplement on a High-protein Diet

Obesity

United States
AstraZeneca

Completed

Study of Ticilimumab in Patients With Metastatic Colorectal Cancer Whose Disease Had Progressed After Treatment

Colorectal Neoplasms

United States, Canada
Tessa Therapeutics
Bristol-Myers Squibb

Active, not recruiting

Autologous CD30.CAR-T in Combination With Nivolumab in cHL Patients After Failure of Frontline Therapy (ACTION)

Classical Hodgkin Lymphoma | Hodgkin Disease Recurrent | Hodgkin Disease Refractory

United States
Biotronik SE & Co. KG

Completed

Eluna Family / Sentus BP Master Study

Heart Failure | Bradycardia

Denmark, Hong Kong, Austria, Germany, Belgium
University Health Network, Toronto
Sunnybrook Health Sciences Centre; Unity Health Toronto

Recruiting

Conventional-therapy & FES-therapy In-Veritas Effects Study (C-FIVE)

C5 Palsy

Canada
Insel Gruppe AG, University Hospital Bern

Not yet recruiting

PRONTO Trial (PRophylactic Versus ON-demand Use of TOcilizumab) (PRONTO)

Lymphoma | Leukemia | Myeloma

Switzerland
University of Freiburg

Completed

Multicenter Study Using IMC to Analyze the Impact of ICANS on Microglia

CAR T-Cell-Related Encephalopathy Syndrome | ICANS, Grade Unspecified

Germany
Sichuan University
Chengdu Brilliant Pharmaceutical Co., Ltd.

Not yet recruiting

Phase I Clinical Study of α-PD-L1/DLL3 CAR-T in Patients With R/R SCLC

Small Cell Lung Cancer Extensive Stage
Institute of Hematology & Blood Diseases Hospital

Recruiting

A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With Primary Plasma Cell Leukemia

Plasma Cell Leukemia

China
University of California, Berkeley
University of Nevada, Reno; World Bank; L'Office National de Nutrition, Madagascar

Recruiting

Integrating Early Stimulation and Play at Scale: "MAHAY Mikolo"

Early Childhood Development

Madagascar
Shenzhen Geno-Immune Medical Institute

Recruiting

NGS-MRD Assessment of Combination Immunotherapies Targeting B-ALL

B-Cell Acute Lymphoblastic Leukemia

China
Sichuan University

Recruiting

CXCR4 Modified Anti-BCMA CAR T Cells for Multiple Myeloma

Multiple Myeloma

China
Biotronik SE & Co. KG

Completed

Remote Follow-up of Patients Receiving Implantable Cardioverter Defibrillator for Prophylactic Therapy (REFORM)

Ventricular Fibrillation | Ventricular Tachycardia

Germany, Czech Republic
Shanxi Province Cancer Hospital
Novatim Immune Therapeutics (Zhejiang) Co., Ltd.

Recruiting

Targeting CD19 and BCMA CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

China
Institute of Hematology & Blood Diseases Hospital...

Recruiting

A Study of VRd-based Regimen Combined With CART-ASCT-CART2 Treatment in NDMM Patients With P53 Abnormalities

Multiple Myeloma

China

Search clinical trials for: CAR-T

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Djibouti

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations